Cencora Inc., US03073E1055

Cencora stock: Wells Fargo lifts target to 400 dollars

Published on 11/20/2026 at 13:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Wells Fargo kept its Overweight rating on Cencora stock while raising its valuation view. The bank cited strong quarterly momentum and relative valuation potential.

Analyst view supports valuation case

  • Wells Fargo kept its Overweight rating and cited strong fourth-quarter momentum.
  • The bank sees relative valuation as an opportunity if Cencora maintains its growth path.
  • The company is entering fiscal 2027 after reporting fourth-quarter results and issuing its outlook.
Cencora Inc., US03073E1055, Illustration mit AI erstellt.

Wells Fargo raised its price target for Cencora on November 17, 2026, while maintaining its Overweight rating, according to Markets Insider. The bank lifted its target from 395 US dollars to 400 US dollars.

Cencora stock traded at 314.00 euros on Lang & Schwarz at 13:04 CET on Friday, November 20, 2026. The quote provides the current trading context for investors following the latest broker assessment.

Wells Fargo sees operating momentum

Wells Fargo said momentum in Cencora's fiscal fourth quarter remained strong and had arguably improved when compared with the difficult US healthcare comparison from fiscal fourth quarter 2025. The bank also continued to view relative valuation as an opportunity, provided growth remains on track.

The analyst action adds to a series of broker views issued as Cencora moves into fiscal 2027. Barclays raised its target to 415 US dollars from 350 US dollars on November 18 and retained an Overweight rating, according to a separate Markets Insider report. The different targets show that analysts continue to focus on the balance between Cencora's growth outlook and its valuation against pharmaceutical distribution peers.

Fiscal 2027 outlook remains central

Cencora reported its fiscal fourth-quarter results on November 4 and issued its initial fiscal 2027 outlook. The company's next steps include executing against that outlook while investors assess demand, healthcare comparisons and the contribution of its specialty businesses.

Cencora Inc. stock facts

  • Company: Cencora Inc.
  • ISIN: US03073E1055
  • Lang & Schwarz quote: 314.00 euros at 13:04 CET on November 20, 2026
  • Wells Fargo target: 400 US dollars, raised from 395 US dollars
  • Rating: Overweight

The broader US market remains the relevant backdrop, with the S&P 500 as the reference index.

More news and analyses on Cencora stock

Disclaimer...
en | US03073E1055 | CENCORA INC. | boerse | 70539898 | bgmi